InvestNot yet confirmed elsewhere1 publisher2 min readPublished
Philips tells Lumify ultrasound users to keep backup scanners after four reported deaths
Philips told all Lumify handheld ultrasound customers to keep backup scanners on hand after a device issue linked to four deaths and eight serious injuries. The FDA says ambulance and field crews face the greatest risk, because clearing the fault takes a Wi-Fi or cellular signal that is harder to find outside the hospital.
The Investor · Invest desk
Ambulance and field crews: greater risk, as signal access is more limited. Pre-hospital patients: reported events stopped scans, delayed care. Remote care: FDA says lost function may matter more. All customers: Philips recommends signal-only use unless a backup is at hand.
- exposure Ambulance and field crews Greater risk outside the hospital because access to Wi-Fi or cellular signal is more limited, claim 7
- exposure Pre-hospital patients Reported re-registration events stopped scans and delayed care, all outside Wi-Fi or cellular range, claim 8
- exposure Mobile and remote care FDA says losing function in these settings may have greater consequences than with a traditional ultrasound device, claim 13
- constraint All Lumify customers Philips recommends using Lumify only where Wi-Fi or cellular signal is readily available, unless a backup is at hand, claim 4
| Who | How | Kind | Claim |
|---|---|---|---|
| Ambulance and field crews | Greater risk outside the hospital because access to Wi-Fi or cellular signal is more limited | exposure | 7 |
| Pre-hospital patients | Reported re-registration events stopped scans and delayed care, all outside Wi-Fi or cellular range | exposure | 8 |
| Mobile and remote care | FDA says losing function in these settings may have greater consequences than with a traditional ultrasound device | exposure | 13 |
| All Lumify customers | Philips recommends using Lumify only where Wi-Fi or cellular signal is readily available, unless a backup is at hand | constraint | 4 |
What happened
- The Lumify app can stop recognising a transducer it has already registered and demand re-registration without warning, which blocks scanning until that step is done.
- Philips has received reports of the fault preventing scans and delaying care in pre-hospital settings, and all of those events happened out of Wi-Fi or cellular range.
- Separately, Philips reported that the USB cable linking the transducer to a user's phone or tablet can disconnect or become unstable during a scan.
Why it matters
- constraint The restriction falls hardest on mobile, underserved and remote care. The FDA lists these settings among the device's purposes and says a failure there does more harm than one on a conventional scanner.
- exposure Philips cannot yet scope a fix for the cable fault, or what it will cost, because it is still working out the cause. That part of its bill has no limit yet.
- decision Ambulance and field services choosing a handheld scanner now have reason to check whether a probe needs a network connection before it will scan.
Philips's letter keeps the Lumify in use under new instructions [3]. Customers are to use the probe only where Wi-Fi or cellular signal is readily accessible "unless a backup ultrasound device is immediately available" [4]. The letter also asks them to circulate it to every user and post a notice beside each unit [15].
In an ambulance or an aircraft, "immediately available" means on board, or more precisely, in the crew's hands at the moment the app asks to re-register a probe [4][6]. The FDA's summary of the letter does not say how many units are affected, or that Philips will supply the backups it asks customers to keep [3].
By September 29, Philips had reported twelve serious outcomes [16], five days after the letter went out [17]. The FDA attributes them to "this issue", singular, in an alert that describes two separate faults [1][10].
The system is a Philips transducer and the Philips Lumify app running on a compatible Android or iOS phone or tablet [12]. The registration fault is in software Philips writes. The cable fault is at the connection to a tablet or phone the customer owns [10]. If the software update arrives within weeks, Philips pays for a release and a second letter, and customers carry spare equipment for those weeks [9]. The FDA said it is still reviewing information and will update the alert as significant new information becomes available [14].
We think customers carry most of the cost for now. The only remedy in place is a second device that they buy, store and carry, and the instruction covers every Lumify system [3][4]. We would be wrong if Philips's follow-up letter offers loaner units or credits, or if the fix takes long enough that the FDA's review asks more of Philips than a letter.
What to watch
- Philips's follow-up letter: when the registration software update ships, and whether it offers customers anything toward the cost of backup equipment.
- Any FDA update to the alert after its review, including a revised count of serious injuries and deaths.
- What Philips identifies as the cause of the USB cable disconnections, and whether the remedy is software or new hardware.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence58
- Adoption
- Insufficient
- Hype gap0
- Incentives
- Insufficient
- Confidence62
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
As of September 29, 2026, Philips Ultrasound has reported eight serious injuries and four deaths associated with this issue.
ReportedSupportedSource: FDA Early Alert2 sources— create a free account to open themView cited source - [2]
FDA's CDRH issued an Early Alert to notify the public of a potentially high-risk device issue involving Philips Ultrasound's Lumify diagnostic ultrasound systems.
- [3]
On September 24, 2026, Philips Ultrasound sent all affected customers a letter recommending that all Lumify diagnostic ultrasound systems have updated use instructions.
- [4]
Philips's letter recommends: "To prevent unintended loss or delays in scanning functionality, only use the Lumify diagnostic ultrasound system in areas with readily accessible Wi-Fi/cellular signals unless a backup ultrasound device is immediately available."
ReportedSupportedSource: Philips Ultrasound customer letter, as reproduced by the FDAView cited source - [5]
Philips's letter recommends: "Always have backup ultrasound devices and/or modalities available for care."
ReportedSupportedSource: Philips Ultrasound customer letter, as reproduced by the FDAView cited source - [6]
Due to a software issue, the Lumify Android or iOS app may not recognize a previously registered transducer and will prompt users for re-registration without warning before point-of-care use; scanning is prevented until registration is completed, and registration requires Wi-Fi or cellular signal access.
- [7]
Lumify devices used outside the hospital, such as in ambulances, aircraft or field settings, are at greater risk due to more limited access to Wi-Fi/cellular signals.
- [8]
Philips has received reports that unexpected re-registration events prevented scanning in pre-hospital environments and delayed care to patients; these events occurred outside Wi-Fi or cellular access.
- [9]
Philips stated it is developing a software update to address the registration issue and will send a follow-up communication once the update is available.
- [10]
Philips reported that the connection between the Lumify transducer USB cable and a customer's tablet or phone may disconnect or be unstable during use, which may disrupt the device and delay care.
- [11]
Philips stated it is working to assess the cause of the USB connection issue and identify an appropriate solution.
- [12]
The Philips Lumify system consists of a Philips transducer, the Philips Lumify application, and a compatible Android or iOS device.
- [13]
The FDA says Lumify is intended for point-of-care use, including access to diagnostic capabilities in mobile, underserved or remote settings, so loss of function may have greater consequences than with traditional ultrasound devices.
- [14]
The FDA is currently reviewing information about the issue and will update the web page as significant new information becomes available.
- [15]
Philips's letter asks customers to circulate the letter to all users of the device and post the Philips notice near the affected units.
ReportedSupportedSource: Philips Ultrasound customer letter, as reproduced by the FDAView cited source - [16]
Philips had reported twelve serious outcomes (serious injuries plus deaths) associated with the issue as of September 29, 2026.
- [17]
The September 29 count came five days after Philips's September 24 customer letter.
Sources
1 independent publisher whose own reporting we read for this story.
- issued an early alert
fda.gov
1 article · October 11, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Entities
- PhilipsFollow
- Philips LumifyFollow
- US Food and Drug AdministrationFollow
- FDA Center for Devices and Radiological HealthFollow